Chemical Component Summary

Name(2S,5R)-7-oxo-6-(sulfooxy)-1,6-diazabicyclo[3.2.1]octane-2-carboxamide
SynonymsAvibactam
Identifiers[(2~{S},5~{R})-2-aminocarbonyl-7-oxidanylidene-1,6-diazabicyclo[3.2.1]octan-6-yl] hydrogen sulfate
FormulaC7 H11 N3 O6 S
Molecular Weight265.24
TypeNON-POLYMER
Isomeric SMILESC1C[C@H](N2C[C@@H]1N(C2=O)OS(=O)(=O)O)C(=O)N
InChIInChI=1S/C7H11N3O6S/c8-6(11)5-2-1-4-3-9(5)7(12)10(4)16-17(13,14)15/h4-5H,1-3H2,(H2,8,11)(H,13,14,15)/t4-,5+/m1/s1
InChIKeyNDCUAPJVLWFHHB-UHNVWZDZSA-N

Chemical Details

Formal Charge0
Atom Count28
Chiral Atom Count3
Bond Count29
Aromatic Bond Count0

Drug Info: DrugBank

DrugBank IDDB09060 
NameAvibactam
Groupsapproved
DescriptionAvibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination with metronidazole, and the treatment of complicated urinary tract infections, including pyelonephritis caused by antibiotic resistant-pathogens, including those caused by multi-drug resistant gram-negative bacterial pathogens. As there is limited clinical safety and efficacy data, Avycaz should be reserved for patients over 18 years old who have limited or not alternative treatment options.
Synonyms
  • Avibactam
  • Avibactam sodium
Brand Names
  • Avycaz
  • Zavicefta
IndicationAVYCAZ (ceftazidime-avibactam), in combination with metronidazole, is indicated for the treatment of complicated intra-abdominal infections caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Providencia stuartii, Enterobacter cloacae, Klebsiella oxytoca, and Pseudomonas aeruginosa in patients 18 years or older. AVYCAZ is also indicated for the treatment of complicated urinary tract infections including pyelonephritis caused by the following susceptible microorganisms: Escherichia coli, Klebsiella pneumoniae, Citrobacter koseri, Enterobacter aerogenes, Enterobacter cloacae, Citrobacter freundii, Proteus spp., and Pseudomonas aeruginosa in patients 18 years or older.
Categories
  • Anti-Infective Agents
  • Aza Compounds
  • beta-Lactamase Inhibitors
  • Enzyme Inhibitors
  • OAT3/SLC22A8 Substrates
CAS number1192500-31-4

Drug Targets

NameTarget SequencePharmacological ActionActions
Beta-lactamase TEMMSIQHFRVALIPFFAAFCLPVFAHPETLVKVKDAEDQLGARVGYIELDLN...unknowninhibitor
Beta-lactamase CTX-MMVTKRVQRMMFAAAACIPLLLGSAPLYAQTSAVQQKLAALEKSSGGRLGV...unknowninhibitor
Beta-lactamaseMMRKSLCCALLLGISCSALATPVSEKQLAEVVANTITPLMKAQSVPGMAV...unknowninhibitor
Beta-lactamase SHV-1MRYIRLCIISLLATLPLAVHASPQPLEQIKLSESQLSGRVGMIEMDLASG...unknowninhibitor
Beta-lactamase SHV-2MRYIRLCIISLLATLPLAVHASPQPLEQIKLSESQLSGRVGMIEMDLASG...unknowninhibitor
View More
Drug Info/Drug Targets: DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS. Nucleic Acids Res. 2011 Jan; 39 (Database issue):D1035-41. | PMID:21059682

Related Resource References

Resource NameReference
CCDC/CSDFUBDUE
PubChem9835049
PubChem90333665
ChEBICHEBI:85984
ChEMBLCHEMBL1689063